MedTrace Logo

Topical Ruxolitinib for the Treatment of Vitiligo

NCT02809976 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-08-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.

Conditions

  • Vitiligo

Interventions

DRUG

Ruxolitinib 1.5% Phosphate Cream

twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20

Sponsors & Collaborators

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • David Rosmarin, MD · Tufts Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-01-31
Completion
2017-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02809976 on ClinicalTrials.gov